Advanced Search:
Equity Index Forex Crypto Commodity

LNTH - Lantheus Holdings

$75.53  -2.65 (-3.39%)

Updated: 13:43 May 5, 2024 EST

Next Hour's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Session's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Week's AI Forecast

N/A

Trend's Accuracy (AI)

N/A

Lantheus Holdings's Position Within the Drug Manufacturers - Specialty & Generic Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

LANTHEUS HOLDINGS - HISTORICAL DATA 6M

  • Last price

    $ 75.53

  • Daily change

    $ -2.65

  • Previous Close

    $ 78.18

  • Last Updated

    13:43 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
-3.51 1.31 0.55 0.14 -0.12

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
3.51 2.33 2.09 2.46 2.38

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A 79% 85.53% 88.62%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0 -100% 67.84 8.01% 62.81 0.19% 62.69

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1.17 73.12 4.52 53.92

Lantheus Holdings Technical Analysis News

Lantheus Holdings

201 Burlington Road
South Building
Bedford, MA 01730
United States
978 671 8001
https://www.lantheus.com

Sectors: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
F. Time Employees: 834
Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Corporate Governance

Lantheus Holdings, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 4. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 2; Compensation: 2.

LANTHEUS HOLDINGS'S HOLDERS RANK

List of holders with stock participation in Lantheus Holdings.

Holder Rank Holder Shares Date Reported % Out Value